Ellis-van Creveld syndrome (EvC) is a chondral and ectodermal dysplasia caused by biallelic mutations in the EVC, EVC2 and WDR35 genes. A proportion of cases with clinical diagnosis of EvC, however, do not carry mutations in these genes. To identify the genetic cause of EvC in a cohort of mutation-negative patients, exome sequencing was undertaken in a family with 3 affected members, and mutation scanning of a panel of clinically and functionally relevant genes was performed in 24 additional subjects with features fitting/overlapping EvC. Compound heterozygosity for the c.2T>C (p.Met1?) and c.662C>T (p.Thr221Ile) variants in DYN-C2LI1, which encodes a component of the intraflagellar transport-related dynein-2 complex previously found mutated in other short-rib thoracic dysplasias, was identified in the 3 affected members of the first family. Targeted resequencing detected compound heterozygosity for the same missense variant and a truncating change (p.Val141*) in 2 siblings with EvC from a second family, while a newborn with a more severe phenotype carried 2 DYNC2LI1 truncating variants. Our findings indicate that DYNC2LI1 mutations are associated with a wider clinical spectrum than previously appreciated, including EvC, with the severity of the phenotype likely depending on the extent of defective DYNC2LI1 function.
atrium most commonly), atrioventricular canal defect, defects of the mitral and tricuspid valves, patent ductus arteriosus, ventricular septal defects, and hypoplastic left heart syndrome. 3, 4 EvC is caused by biallelic mutations in EVC (MIM 604831) or EVC2 (MIM 607261). [5] [6] [7] These genes encode transmembrane proteins that localize to primary cilia and act downstream of the 7-transmembrane protein smoothened (SMO; MIM 601500) to promote hedgehog (Hh) signal transduction. 8, 9 Consistently, accumulating evidence indicates that EvC is caused by impaired Hh signaling in cardiac, skeletal and orofacial tissues during embryonic development. 10 While the clinical features of patients with EvC appear to be similar regardless of whether the disorder is caused by mutations affecting EVC or EVC2, 6, 7 has been documented to be required for EVC/EVC2 recruitment into the ciliary compartment, and proper cell response to Hh signals, providing further evidence for defective Hh signaling as the pathogenetic mechanism underlying EvC.
Based on our previous finding that a significant proportion of patients with a clinical diagnosis of EvC do not have mutations in any of the identified disease genes, 11, 12 we performed whole-exome sequencing (WES) in a family segregating EvC proved to be EVC/ EVC2/WDR35 mutation-negative, and analyzed a panel of candidate genes by targeted resequencing in 24 additional subjects also molecularly negative for known EvC genes, but diagnosed with EvC or having features overlapping with this condition, to investigate further the molecular genetics of this disorder. We report that a specific combination of variants in DYNC2LI1, a gene that had previously been shown mutated in other short-rib thoracic dysplasias (SRTDs), including Jeune syndrome, accounts for a small proportion of EvC cases.
Our findings suggest that the severity of the phenotype associated with DYNC2LI1 mutations depend on the extent of defective DYN-C2LI1 function.
| PATIENTS AND METHODS

| Patients
A cohort of 25 unrelated subjects with features fitting EvC or suggestive for this disease were included in the study. Clinical assessment was performed by experienced clinical geneticists, and all subjects had previously been tested negative for mutations in the EVC, EVC2 and WDR35 genes. In all subjects, chromosome and high-resolution CGH array analysis excluded the occurrence of clinically relevant CNVs. Clinical data and biological material collection, use and storage were attained after written informed consent was secured, in accordance with the ethical standards of the responsible institutional committees on human experimentation. Written informed consent was obtained from the parents for patients' photos publication.
| Whole-exome sequencing
WES was performed in a single affected individual, BL1304-12 (V-2, family 1), from a medium-sized family with 3 affected members having clinical diagnosis of EvC ( Figure 1 and Table 1 ). DNA was obtained from leukocytes. Exome capture was carried out using Nextera rapid capture v1.2 (Illumina, San Diego, CA), and sequencing was performed on a NextSeq 500 platform (Illumina). WES data were processed and analyzed using an in-house implemented pipeline as previously described. [13] [14] [15] [16] Briefly, high-quality variants were filtered against public databases 3 | RESULTS
| Molecular analyses
Data analysis of the WES performed in subject BL1304-12 allowed to identify 80 179 high-quality variants, of which 14 996 were predicted to have functional impact (missense, nonsense and frameshift changes, small indels, and splice site changes). Among the latter, 526 private, rare and clinically associated variants were retained for further analysis (Table S1) Figure S1 ). The disruptive c.2T>C change had previously been reported (rs200859699; total MAF < 0.0001, ExAC), while the missense substitution, c.662C>T, had been described as disease-causing in a subject with a Jeune-like phenotype. 21 None of the 2 variants had previously been annotated in the available population-matched in-house database (approximately 800 exomes), and both variants were predicted to be damaging (Table 2) . with clinical diagnosis of EvC, and in a sporadic case (MGM14-1183, family 3) exhibiting a more severe phenotype ( Figure 1 and Table 1 ).
MGM03-0553 and MGM03-0552 were heterozygous for a maternally transmitted truncating variant (c.420delA, p.Val141*) and the previously identified missense change, c.662C>T (p.Thr221Ile), which was inherited from the father. MGM14-1183 was a compound heterozygote for a frameshift change (c.123_124insA, p.Gly42Argfs *12) and an intronic variant close to the exon 8 acceptor splice site (c.658-11delT). The variants, which were either rare or private, were validated by Sanger sequencing, and proved to co-segregate with disease ( Table 2 and Figure S1 ). No gene with functionally relevant biallelic variants or de novo changes was identified in the other subjects. DNA from P2 (sibling of P1) and P3 (fetus after terminated pregnancy from the same family) was not available for molecular analysis. To confirm pathogenicity of c.658-11delT, the functional impact of the variant on DYNC2LI1 transcript processing was assessed. As biological material of subject MGM14-1183 was not available for the study, total RNA extracted from leukocytes of her parents was retrotranscribed and used to scan the entire DYNC2LI1 coding sequence and 3 0 -UTR, demonstrating allele-specific transcript decay associated with the c.658-11delT variant. Sequencing of the DYNC2LI1 cDNA in both parents, identified 2 informative SNPs that served to document loss of the maternal DYNC2LI1 mRNA transcribed from the allele containing the splice site change, thus providing direct evidence for the disruptive impact of the variant on transcript processing (Table S3 ).
| Clinical features of DYNC2LI1 mutationpositive subjects
Clinical data of the 6 affected subjects are summarized in Table 1, and are compared with the features characterizing EvC and Jeune syndrome.
As anticipated, affected members in families 1 and 2 had features within the clinical spectrum of EvC. In family 1, the phenotype of the 3 affected subjects was homogeneous. The 2 siblings, SC741D1 and SC742D1, had previously been clinically described. 22 The older sister, (Table 1) . 25 Clinical features of these cases were considered to be similar to those occurring in SRTD3 (MIM 613091) and SRTD11 (MIM 615633), which are respectively caused by mutations in the DYNC2H1 and WDR34 genes. 26, 27 Independently, compound heterozygous DYNC2LI1 mutations have been reported in a single family with 3 affected siblings sharing features suggestive of Jeune syndrome and clinically overlapping EvC (Table 1) . 21 In the present series, almost 5 of 6 affected individuals showed an apparent homogeneous, milder phenotype fitting EvC.
Shared/recurrent features in these patients included congenital heart defect (particularly atrioventricular canal defect), median cleft lip with multiple oral frenula, and ectodermal defects, all of which are typical signs for EvC. In these subjects, chest narrowing was less evident compared with that occurring in patients with Jeune syndrome. Consistently, 4 subjects reached adulthood and none of them suffered respiratory complications during infancy. In addition, polydactyly and oral features, including oral fenula, cleft lip, hypodontia and abnormal teeth, and ectodermal defects, such as dysplastic nails, do not usually occur in Jeune syndrome. 24 Overall, the clinical phenotype of affected subjects from families 1 and 2 of this report strongly resembled EvC, and comparison between these subjects and EVC/ EVC2 mutation-positive EvC cases did not reveal any significant difference in clinical features except for the stature that was observed within the normal range in the 5 subjects with biallelic DYNC2LI1
mutations. Remarkably, besides the occurrence of a truncating mutation, the c.662C>T missense change was a common finding of patients sharing the EvC phenotype, including the cases previously reported by Kessler et al. 21 The nucleotide substitution affects a highly conserved threonine among vertebrate orthologues, and was suggested to have a disruptive impact on nucleoside triphosphate hydrolase function. 21 Overall, this finding suggests that compound heterozygosity for this specific missense change, which probably acts as a hypomorphic mutation, can result in a variable clinical spectrum having Jeune syndrome and EvC as recognized nosologic entities.
In conclusion, the present findings demonstrate that biallelic DYN-C2LI1 mutations account for a small proportion of EvC. Together with previously reported observations, these data also document that DYN-C2LI1 mutations are associated with a wide phenotypic spectrum, and suggest the presence of genotype-phenotype correlations, with the c.662C>T being specifically associated with a distinctive form of EvC.
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